Insulet Corporation ($PODD) Stock Forecast: Down 7.1% Today

What is Insulet Corporation?

PODD is the ticker symbol for Insulet Corporation, a company specializing in insulin delivery devices. The overall market sentiment for Insulet Corporation today was bearish.

Why is Insulet Corporation going down?

PODD stock is down 7.1% on Mar 13, 2026 17:06

• Insulet Corporation's stock (PODD) experienced a significant bearish movement following the announcement of a voluntary recall of specific Omnipod 5 Pods due to a risk of internal leaks, leading to under-delivery of insulin and causing serious adverse events, including hospitalizations and diabetic ketoacidosis.
• The recall of defective Omnipod insulin delivery devices has raised concerns among investors, leading to a negative impact on Insulet's stock price.
• The anticipated recall-related costs of up to $40 million for 2026 have also contributed to the bearish sentiment surrounding Insulet Corporation.
• The analysis of Insulet's valuation, indicating undervaluation based on Discounted Cash Flow (DCF) model but overvaluation based on Price-to-Earnings (P/E) ratio, further adds to the uncertainty and downward pressure on the stock price.

PODD Price Chart

PODD Technical Analysis

PODD News

Insulin devices recalled over leak risk, reports of 'serious adverse events'

Insulet Corporation has issued a voluntary recall of specific Omnipod 5 Pods due to a risk of internal leaks that can prevent full insulin delivery. The company has received 18 reports of serious adverse events, including hospitalizations and diabetic ketoacidosis, linked to high blood glucose levels from under-delivery of insulin. Customers are advised to check their pod lot numbers and request free replacements, contacting Insulet Product Support for assistance.

https://www.fox5atlanta.com/news/insulin-devices-recalled-over-leak-risk-reports-serious-adverse-events

Insulet reports 18 serious adverse events with recall of Omnipod 5 insulin pumps

Insulet is recalling specific lots of its Omnipod 5 insulin patch pumps due to a small tear in the internal tubing that can lead to insulin leaking inside the pod, causing under-delivery. The company has reported 18 serious adverse events, including hospitalizations and diabetic ketoacidosis, but no deaths. Insulet anticipates up to $40 million in recall-related costs for 2026 but maintains its revenue growth expectations.

https://www.medtechdive.com/news/insulet-reports-18-serious-adverse-events-with-recall-of-omnipod-5-insulin/814689/

Insulet recalling certain defective Omnipod insulin delivery devices

Insulet is initiating a recall of specific defective Omnipod insulin delivery devices. The recall targets certain products that have been identified as faulty, indicating a potential safety concern for users of these devices.

https://www.msn.com/en-us/money/companies/insulet-recalling-certain-defective-omnipod-insulin-delivery-devices/ar-AA1YyslT

Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness

This article analyzes Insulet (PODD) following recent share price weakness, employing Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio analyses to assess its valuation. While the DCF model suggests Insulet is undervalued by 19.2% at US$295.58 per share compared to its current price of US$238.82, its P/E ratio of 68.04x is found to be overvalued compared to its industry average and Simply Wall St's Fair Ratio of 32.64x. The article encourages investors to use Simply Wall St's "Narratives" feature for a more personalized valuation approach.

https://www.sahmcapital.com/news/content/is-it-time-to-reassess-insulet-podd-after-recent-share-price-weakness-2026-03-12

Insulet recalls some insulin devices in US over leakage risk

Insulet has issued a recall for specific batches of its Omnipod 5 insulin-delivery pods in the U.S. due to a manufacturing defect that could prevent diabetic users from receiving their full insulin dose. This defect, a small tear in internal tubing, can lead to insulin leakage within the device, potentially causing high blood sugar levels or a dangerous condition requiring urgent medical care. The company has reported 18 serious adverse events, including hospitalizations, and has notified the U.S. Food and Drug Administration.

https://www.reuters.com/business/healthcare-pharmaceuticals/insulet-recalls-some-insulin-devices-us-over-leakage-risk-2026-03-12/

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 20.2% Today

Ethereum ($ETH) Crypto Forecast: Up 11.6% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.8% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Down 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 7.4% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.6% Today

Bumble Inc. ($BMBL) Stock Forecast: Up 5.6% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.1% Today

Insulet Corporation Price History

10.01.2026 - PODD Stock was up 5.1%

• A significant increase in stake by BI Asset Management Fondsmaeglerselskab A S indicates confidence in Insulet Corporation's future prospects, likely contributing to the bullish movement in the stock.
• The launch of Insulet's Omnipod 5 Automated Insulin Delivery System in new markets like the Middle East showcases the company's commitment to expanding its product offerings and reaching a broader customer base, potentially boosting investor optimism.
• Despite the recent stock decline and trading below analyst targets, the introduction of innovative products such as Omnipod Discover and the company's focus on ecosystem enhancement could be positively received by investors, leading to the bullish market movement.

20.01.2026 - PODD Stock was down 5.8%

• Insulet Corporation (PODD) witnessed a downturn in its stock, despite strong Q4 results and an expansion of its share repurchase program.
• The stock's decline may be linked to JPMorgan Chase & Co. revising Insulet's price target downward from $415.00 to $340.00 due to cautious guidance, despite robust earnings and revenue growth.
• Other factors contributing to the bearish movement include concerns about the company's valuation, competitive landscape in the diabetes market, and technical challenges like trading below its moving averages.
• The market sentiment appears mixed, with positive financial performance offset by underlying uncertainties, resulting in selling pressure on the stock.

19.01.2026 - PODD Stock was down 5.6%

• Despite a strong Q4 performance showing a 31% revenue growth and surpassing earnings expectations, Insulet's stock (PODD) faced a 5.6% decline.
• The market response was negative due to Insulet's conservative short-term outlook, which overshadowed its solid financial results and expansion initiatives.
• A reduction in price target by a major financial institution from $415.00 to $340.00, though still affirming an "overweight" rating, added to the stock's downward trend.
• Investor apprehension regarding the potential effects of the cautious guidance on Insulet's future growth trajectory likely contributed to the stock's decline, despite the positive earnings outcome.

19.01.2026 - PODD Stock was down 6.8%

• A significant number of shares of Insulet Corporation were acquired by Cumberland Partners Ltd, indicating confidence in the company's future prospects.
• Insulet's stock price target was lowered by Canaccord Genuity due to valuation concerns, despite the company reporting strong Q4 earnings and revenue growth.
• Impressive financial results for Q4 and full year 2025 were reported by Insulet, showing consistent revenue growth and strategic developments in the diabetes management market.
• The market may have reacted bearishly to the lowered price target by Canaccord Genuity, overshadowing the positive earnings and growth reported by Insulet.

19.01.2026 - PODD Stock was down 6.0%

• In recent quarters, Insulet Corporation recorded strong Q4 earnings and revenue surpassing expectations. Despite the impressive growth in Omnipod revenues and a positive outlook, the company's stock saw a decline.
• One factor contributing to the stock's downturn is a decrease in Insulet's stock price target by Canaccord Genuity. This adjustment reflects industry valuation compression, despite the strong financial performance of the company.
• The purchase of shares by Cumberland Partners Ltd and other institutional investors initially instilled confidence in the stock but was insufficient to counter the prevailing market sentiment.
• Following Insulet's mention of challenging year-over-year comparisons, investors engaged in profit-taking, resulting in a bearish trend in the stock price.

18.01.2026 - PODD Stock was up 5.3%

• Insulet (PODD) shares rose by 5.6% post the disclosure of robust fourth-quarter financial results that surpassed expectations, attributed to heightened demand for its Omnipod insulin management systems.
• The company's positive projection of a 26% year-over-year sales upsurge for the first quarter of 2026 added to the stock's upward momentum.
• Despite a previous decline of 7.9% since the year's commencement, the recent favorable performance suggests that investors may have found confidence in the company's financial strength and strategic initiatives.
• Insulet's focus on innovation, market expansion, and precise execution in transforming diabetes care likely fostered investor trust, fueling the notable increase in the stock price.

23.00.2026 - PODD Stock was down 5.1%

• Insulet Corporation (PODD) had a bearish movement possibly due to the following reasons:
• Despite surpassing EPS estimates, the company missed revenue expectations, which might have disappointed investors.
• The significant reduction in stake by SG Americas Securities LLC could have signaled a lack of confidence in the company's future performance.
• The appointment of a new CEO at BVI, who was the former CEO of Insulet, might have raised concerns about leadership stability at Insulet.
• Although Stephens Investment Management Group LLC increased its stake, the overall market sentiment could have been influenced by the mixed signals from institutional investors.

18.01.2026 - PODD Stock was up 9.2%

• Following the Q4 2025 earnings announcement, Insulet Corporation (PODD) saw a notable uptrend today.
• While falling slightly short of EPS projections, the company surpassed revenue estimations and achieved a remarkable 31.2% year-over-year revenue expansion.
• An increase of $350 million in share repurchase authorization and optimistic 2026 guidance were divulged, underlining Insulet's financial robustness and confidence in future growth.
• Market reception to Insulet's effective operations, solid business model, and success in diabetes care has bolstered investor trust, propelling the stock price upward in a bullish fashion.

20.10.2025 - PODD Stock was down 6.2%

• The growing short interest could be influencing the stock's decline as more investors are taking positions against the company.
• Despite Insulet's strong performance in the past 15 years, it seems insufficient to counter the prevailing negative market sentiment, resulting in a drop in the stock price.
• Activities in the options market indicate potential insider information or speculative trading affecting the stock, intensifying the bearish outlook.

13.02.2026 - PODD Stock was down 5.2%

• The decline in Insulet's stock (PODD) today is tied to a voluntary correction made by the company concerning specific lots of Omnipod 5 Pods due to a manufacturing problem causing insulin leaks. This has raised concerns about product safety and potential revenue impact.
• Negative information about the insulin leak issue may have overshadowed favorable study results released by Insulet Corporation on a fully closed-loop automated insulin delivery system, which demonstrated promising outcomes for adults with type 2 diabetes. However, the recall news appears to have had a more immediate effect on investor sentiment.
• Furthermore, the decrease in Swiss National Bank holdings may have intensified selling pressure on the stock, suggesting a lack of short-term confidence from institutional investors.
• Despite recent challenges, Insulet's solid Q1 earnings and positive analyst outlook, with a target price of $354.24, suggest favorable long-term growth potential for the company, contingent on resolving the current manufacturing problem and successfully launching their innovative products.

13.02.2026 - PODD Stock was down 7.1%

• Insulet Corporation's stock (PODD) experienced a significant bearish movement following the announcement of a voluntary recall of specific Omnipod 5 Pods due to a risk of internal leaks, leading to under-delivery of insulin and causing serious adverse events, including hospitalizations and diabetic ketoacidosis.
• The recall of defective Omnipod insulin delivery devices has raised concerns among investors, leading to a negative impact on Insulet's stock price.
• The anticipated recall-related costs of up to $40 million for 2026 have also contributed to the bearish sentiment surrounding Insulet Corporation.
• The analysis of Insulet's valuation, indicating undervaluation based on Discounted Cash Flow (DCF) model but overvaluation based on Price-to-Earnings (P/E) ratio, further adds to the uncertainty and downward pressure on the stock price.

13.02.2026 - PODD Stock was down 7.7%

• The bearish movement in Insulet Corporation's stock (PODD) today can be attributed to the following factors:
• The recall of specific lots of Omnipod 5 insulin patch pumps due to a manufacturing issue leading to insulin leakage and serious adverse events like hospitalizations and diabetic ketoacidosis has raised concerns among investors about product safety and potential financial implications.
• The analysis of Insulet's valuation, indicating that the stock may be overvalued based on Price-to-Earnings ratio compared to industry averages, could have prompted profit-taking and selling pressure.
• The reduction in holdings by the Swiss National Bank may have also contributed to the negative sentiment surrounding the stock, signaling reduced institutional confidence in the company's future prospects.
• Despite the recall and valuation concerns, Insulet's strong Q1 earnings performance and analyst recommendations for the stock indicate a mixed outlook, with investors likely monitoring developments closely before making investment decisions.